Abstract 467P
Background
Lung cancer is a serious problem and one of the most common cancer diseases worldwide. Many studies were shown that free-circulating mtDNA levels are increased in the serum/plasma of patients with various malignancies. Here we analysed mtDNA levels in the plasma of patients with NSCLC compared to the health individuals.
Methods
68 patients with NSCLC and 59 healthy individuals were recruited for this study. A quantitative analysis of the free-circulating mtDNA was conducted using the qPCR. To create a standard curve, the purified PCR product of the 490 bp mtDNA fragment was used. The DNA concentration determined using the PicoGreen dsDNA Quantification Kit. The copy number of the free-circulating mtDNA was calculated according to the protocol of Applied Biosystems.
Results
The levels of free-circulating mtDNA in patients with NSCLC were found in range from 2.7x1010 to 6,51x1014 with a mean value 3,04x1013 copies/μL. In plasma samples of healthy subjects the levels of mtDNA copies were found to range from 6,0x109 to 1,73x1013 with a mean value 7,46x1011. Thus, the levels of free-circulating mtDNA in patients with NSCLC were higher in 6.6 times than in those of healthy subjects (P < 0.05).
Conclusions
Results of this study suggest that high free-circulating mtDNA copies number is a promising marker for diagnosis and prediction of non-small cell lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Ministry of Education and Science of the Republic of Kazakhstan (grant no. 1258/GF4).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract